Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Waldenström Macroglobulinemia
NCT05952037Phase 2Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
A Phase 2 trial of sonrotoclax in Waldenström macroglobulinemia (WM), sponsored by BeOne Medicines. Started Oct 2023; status: active, not recruiting.
02
Drugs
sonrotoclax
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05952037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952037.